These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. L-carnitine blood levels and oxidative stress in treated phenylketonuric patients. Sitta A; Barschak AG; Deon M; de Mari JF; Barden AT; Vanzin CS; Biancini GB; Schwartz IV; Wajner M; Vargas CR Cell Mol Neurobiol; 2009 Mar; 29(2):211-8. PubMed ID: 18814025 [TBL] [Abstract][Full Text] [Related]
5. Increased cytokine levels induced by high phenylalanine concentrations in late diagnosis PKU patients compared to early diagnosis: Anti-inflammatory effect of L-carnitine. Faverzani JL; Hammerschmidt TG; Mescka CP; Guerreiro G; Lopes FF; Delgado CA; de Moura Coelho D; Sitta A; Deon M; Wajner M; Vargas CR Cell Biochem Funct; 2023 Jun; 41(4):490-500. PubMed ID: 37170672 [TBL] [Abstract][Full Text] [Related]
6. Urinary biomarkers of oxidative stress and plasmatic inflammatory profile in phenylketonuric treated patients. Deon M; Sitta A; Faverzani JL; Guerreiro GB; Donida B; Marchetti DP; Mescka CP; Ribas GS; Coitinho AS; Wajner M; Vargas CR Int J Dev Neurosci; 2015 Dec; 47(Pt B):259-65. PubMed ID: 26456498 [TBL] [Abstract][Full Text] [Related]
7. L-carnitine protects DNA oxidative damage induced by phenylalanine and its keto acid derivatives in neural cells: a possible pathomechanism and adjuvant therapy for brain injury in phenylketonuria. Faverzani JL; Steinmetz A; Deon M; Marchetti DP; Guerreiro G; Sitta A; de Moura Coelho D; Lopes FF; Nascimento LVM; Steffens L; Henn JG; Ferro MB; Brito VB; Wajner M; Moura DJ; Vargas CR Metab Brain Dis; 2021 Oct; 36(7):1957-1968. PubMed ID: 34216350 [TBL] [Abstract][Full Text] [Related]
8. Low total antioxidant status is implicated with high 8-hydroxy-2-deoxyguanosine serum concentrations in phenylketonuria. Schulpis KH; Tsakiris S; Traeger-Synodinos J; Papassotiriou I Clin Biochem; 2005 Mar; 38(3):239-42. PubMed ID: 15708545 [TBL] [Abstract][Full Text] [Related]
9. Increased peripheral of brain-derived neurotrophic factor levels in phenylketonuric patients treated with l-carnitine. Faverzani JL; Guerreiro G; Hammerschmidt TG; Lopes FF; Coelho DM; Sitta A; Mescka CP; Deon M; Wajner M; Vargas CR Arch Biochem Biophys; 2023 Nov; 749():109792. PubMed ID: 37863349 [TBL] [Abstract][Full Text] [Related]
10. DNA damage induced by alloisoleucine and other metabolites in maple syrup urine disease and protective effect of l-carnitine. Hauschild TC; Guerreiro G; Mescka CP; Coelho DM; Steffens L; Moura DJ; Manfredini V; Vargas CR Toxicol In Vitro; 2019 Jun; 57():194-202. PubMed ID: 30853490 [TBL] [Abstract][Full Text] [Related]
11. DNA damage induced by phenylalanine and its analogue p-chlorophenylalanine in blood and brain of rats subjected to a model of hyperphenylalaninemia. Simon KR; Dos Santos RM; Scaini G; Leffa DD; Damiani AP; Furlanetto CB; Machado JL; Cararo JH; Macan TP; Streck EL; Ferreira GC; Andrade VM; Schuck PF Biochem Cell Biol; 2013 Oct; 91(5):319-24. PubMed ID: 24032682 [TBL] [Abstract][Full Text] [Related]
12. Metabolomics for improved treatment monitoring of phenylketonuria: urinary biomarkers for non-invasive assessment of dietary adherence and nutritional deficiencies. Wild J; Shanmuganathan M; Hayashi M; Potter M; Britz-McKibbin P Analyst; 2019 Nov; 144(22):6595-6608. PubMed ID: 31608347 [TBL] [Abstract][Full Text] [Related]
13. Experimental evidence of oxidative stress in patients with l-2-hydroxyglutaric aciduria and that l-carnitine attenuates in vitro DNA damage caused by d-2-hydroxyglutaric and l-2-hydroxyglutaric acids. Rodrigues DGB; de Moura Coelho D; Sitta Â; Jacques CED; Hauschild T; Manfredini V; Bakkali A; Struys EA; Jakobs C; Wajner M; Vargas CR Toxicol In Vitro; 2017 Aug; 42():47-53. PubMed ID: 28396261 [TBL] [Abstract][Full Text] [Related]
14. Carnitine status in early-treated children, adolescents and young adults with phenylketonuria on low phenylalanine diets. Weigel C; Kiener C; Meier N; Schmid P; Rauh M; Rascher W; Knerr I Ann Nutr Metab; 2008; 53(2):91-5. PubMed ID: 18946205 [TBL] [Abstract][Full Text] [Related]
15. Prevention by L-carnitine of DNA damage induced by 3-hydroxy-3-methylglutaric and 3-methylglutaric acids and experimental evidence of lipid and DNA damage in patients with 3-hydroxy-3-methylglutaric aciduria. Delgado CA; Balbueno Guerreiro GB; Diaz Jacques CE; de Moura Coelho D; Sitta A; Manfredini V; Wajner M; Vargas CR Arch Biochem Biophys; 2019 Jun; 668():16-22. PubMed ID: 31047871 [TBL] [Abstract][Full Text] [Related]
16. Work activity and phenylalanine levels in a population of young adults with classic PKU. Riva MA; Madotto F; Turato M; Salvatici E; Indovina S; Giovannini M; Riva E; Cesana G Med Lav; 2017 Apr; 108(2):118-122. PubMed ID: 28446738 [TBL] [Abstract][Full Text] [Related]
17. Plasma phenylalanine concentrations are associated with hepatic iron content in a murine model for phenylketonuria. Gropper SS; Yannicelli S; White BD; Medeiros DM Mol Genet Metab; 2004 May; 82(1):76-82. PubMed ID: 15110326 [TBL] [Abstract][Full Text] [Related]
18. The effects of sapropterin on urinary monoamine metabolites in phenylketonuria. Douglas TD; Jinnah HA; Bernhard D; Singh RH Mol Genet Metab; 2013 Jul; 109(3):243-50. PubMed ID: 23712020 [TBL] [Abstract][Full Text] [Related]
19. The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria. Elsas LJ; Greto J; Wierenga A Mol Genet Metab; 2011 Apr; 102(4):407-12. PubMed ID: 21216643 [TBL] [Abstract][Full Text] [Related]
20. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Schindeler S; Ghosh-Jerath S; Thompson S; Rocca A; Joy P; Kemp A; Rae C; Green K; Wilcken B; Christodoulou J Mol Genet Metab; 2007 May; 91(1):48-54. PubMed ID: 17368065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]